Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to examine the efficacy of infliximab for the
treatment of persistent uveitis in children. Participants (4-18 years of age) will be
randomly assigned to either 5mg/kg or 10mg/kg dose of infliximab to be administered by
intravenous infusion at four week intervals. Participant responses will be measured at at
four to eight week intervals for up to ten months.
Phase:
Phase 4
Details
Lead Sponsor:
Egla C. Rabinovich
Collaborator:
Childhood Arthritis and Rheumatology Research Alliance